News/PR Newswire/Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022This news item displays a headline only and has no other text.Chinese stocksPR NewswireStrategy, business, and products© Copyright 2026 Cision US Inc. All Rights Reserved.Show moreRead more from PR Newswire
